J&J eyes prostate cancer label expansion for Akeega
Pharmaceutical Technology
JULY 7, 2025
Find out more J&Jās drug is an option for patients where medical or surgical treatment to lower testosterone levels has not worked, and in those who have BRCA 1/2 mutations ā a subset of homologous recombination repair (HRR) mutations ā in whom chemotherapy is not indicated. Give your business an edge with our leading industry insights.
Let's personalize your content